Communiqués United Therapeutics Corporation

Actions

UTHR

US91307C1027

Produits pharmaceutiques

Temps réel estimé Cboe BZX 18:30:41 04/09/2026			Varia. 5j.	Varia. 1 janv.
491,12 ^USD	+0,18%		-4,65%	+0,87%

02/09	Un dirigeant de United Therapeutics a vendu des actions pour une valeur de 4 883 839 $, selon une récente déclaration à la SEC	MT
02/09	United Therapeutics Corporation annonce l’acceptation par la FDA d’une demande complémentaire d’autorisation de mise sur le marché pour Tyvaso nébulisé dans le traitement de la fibrose pulmonaire idiopathique	CI

Communiqués

02/09	United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis	BU
01/09	United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences	BU
31/08	United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026	AQ
28/08	United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026	BU
24/08	United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension	BU
17/08	United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis	BU
05/08	United Therapeutics: Q2 Earnings Snapshot	AQ
05/08	United Therapeutics Corporation Reports Second Quarter 2026 Financial Results	BU
29/07	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet	BU
23/07	United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors	BU
22/07	United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026	BU
02/07	United Therapeutics Corporation Acquires Thymmune Therapeutics	BU
29/06	United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion	BU
27/05	United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference	BU
18/05	United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026	BU
18/05	United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial	AQ
17/05	United Therapeutics : Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026	PU
17/05	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026	BU
16/05	United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial	BU
12/05	United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference	BU
11/05	United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026	BU
06/05	United Therapeutics : First Quarter 2026 Financial Results Presentation	PU
06/05	United Therapeutics : First Quarter 2026 Factsheet	PU
06/05	United Therapeutics: Q1 Earnings Snapshot	AQ
06/05	United Therapeutics Corporation Reports First Quarter 2026 Financial Results	BU